Published in Drug Des Devel Ther on March 10, 2011
Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer (2012) 1.47
Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol (2013) 1.12
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. Clin Med Insights Oncol (2015) 0.90
Cytoskeleton targeting value in prostate cancer treatment. Am J Clin Exp Urol (2014) 0.90
Preclinical profile of cabazitaxel. Drug Des Devel Ther (2014) 0.85
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer. Biomedicine (Taipei) (2014) 0.84
Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system. Int J Nanomedicine (2014) 0.81
New therapeutics to treat castrate-resistant prostate cancer. ScientificWorldJournal (2013) 0.79
Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent manner. PLoS One (2014) 0.78
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget (2015) 0.78
The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer. Biomed Res Int (2015) 0.77
Inhibitory effects of chemotherapeutics on human organic anion transporter hOAT4. Int J Biochem Mol Biol (2016) 0.75
The unfolding treatment landscape for men with castration-resistant prostate cancer. Clin Investig (Lond) (2011) 0.75
Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer. Cancers (Basel) (2011) 0.75
Texas Native Plants Yield Compounds with Cytotoxic Activities against Prostate Cancer Cells. J Nat Prod (2016) 0.75
Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers. Am J Transl Res (2016) 0.75
Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre. Case Rep Oncol (2016) 0.75
Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells. Mol Cancer Ther (2016) 0.75
Management of metastatic castration-resistant prostate cancer. Eur Urol Rev (2011) 0.75
ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer. Mol Cancer Ther (2017) 0.75
Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity. World J Urol (2014) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 3.98
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30
Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol (2002) 2.01
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol (2008) 1.80
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
Tubulin-interactive natural products as anticancer agents. J Nat Prod (2009) 1.59
Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med (2010) 1.26
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol (1998) 1.26
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol (1998) 1.04
Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging (2010) 0.96
Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm (2006) 0.89
Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp (2002) 0.89
Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. Clin Genitourin Cancer (2010) 0.86
Cabazitaxel for castration-resistant prostate cancer. Lancet (2011) 0.84
Cabazitaxel for castration-resistant prostate cancer. Lancet (2011) 0.78
Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer. Oncology (Williston Park) (2010) 0.78
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol (2013) 1.22
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer (2011) 1.20
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res (2010) 1.05
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urol Oncol (2011) 0.99
Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl (2012) 0.98
Clinical problem-solving. Beware of first impressions. N Engl J Med (2008) 0.97
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett (2012) 0.95
Tumorigenic potential of circulating prostate tumor cells. Oncotarget (2013) 0.94
Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev (2014) 0.92
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate (2014) 0.92
Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am (2013) 0.92
Surgical resection of malignant melanoma metastatic to the pancreas: case series and review of literature. J Gastrointest Cancer (2012) 0.90
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci (2013) 0.89
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate (2014) 0.88
Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol (2013) 0.87
Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. Hum Vaccin Immunother (2012) 0.86
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate (2011) 0.84
Prostate angiosarcoma: a case report and literature review. Med Oncol (2012) 0.83
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. Am J Cancer Ther Pharmacol (2014) 0.82
Prostate angiosarcoma: is there any association with previous radiation therapy? BJU Int (2012) 0.82
Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid (2013) 0.82
Update: immunological strategies for prostate cancer. Curr Urol Rep (2010) 0.82
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis. Oncology (Williston Park) (2014) 0.81
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate (2011) 0.81
Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol (2012) 0.81
Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med (2014) 0.80
Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer. Clin Genitourin Cancer (2013) 0.79
Rheumatoid arthritis masked by docetaxel chemotherapy in a patient with ovarian carcinoma. J Clin Rheumatol (2008) 0.78
Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother (2015) 0.77
Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol (2012) 0.77
Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. Curr Opin Endocrinol Diabetes Obes (2016) 0.76
Abiraterone acetate: a hat trick of clinical benefits. Lancet Oncol (2012) 0.76
Abiraterone for the Treatment of Advanced Prostate Cancer. Int J Target Ther Cancer (2012) 0.75
The unfolding treatment landscape for men with castration-resistant prostate cancer. Clin Investig (Lond) (2011) 0.75
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer. Urol Clin North Am (2012) 0.75
A cut above. Am J Med (2007) 0.75
Acute psychological stress-induced water intoxication. Int J Psychiatry Clin Pract (2005) 0.75